Nine prohibited stimulants found in sports and weight loss supplements: deterenol, phenpromethamine (Vonedrine), oxilofrine, octodrine, beta-methylphenylethylamine (BMPEA), 1,3-dimethylamylamine (1,3-DMAA), 1,4-dimethylamylamine (1,4-DMAA), 1,3-dimethylbutylamine (1,3-DMBA) and higenamine.


Journal

Clinical toxicology (Philadelphia, Pa.)
ISSN: 1556-9519
Titre abrégé: Clin Toxicol (Phila)
Pays: England
ID NLM: 101241654

Informations de publication

Date de publication:
Nov 2021
Historique:
pubmed: 24 3 2021
medline: 9 11 2021
entrez: 23 3 2021
Statut: ppublish

Résumé

Weight loss and sports supplements containing deterenol have been associated with serious adverse events including cardiac arrest. To determine the presence and quantity of experimental stimulants in dietary supplements labeled as containing deterenol sold in the United States. Dietary supplements available for sale in the US and labeled as containing deterenol or one of its synonyms (e.g., isopropylnorsynephrine and isopropyloctopamine) were purchased online. For each brand, one container or subsample was analyzed by NSF International (Ann Arbor, MI) and one container or subsample by the Netherland's National Institute for Public Health and the Environment (RIVM, Bilthoven, The Netherlands). When differences existed between the two containers or subsamples of the same brand, both products were reanalyzed by Sciensano (Brussels, Belgium). NSF International carried out qualitative and quantitative analyses using ultra-high-performance liquid chromatography (UHPLC) quadrupole-Orbitrap mass spectrometry. RIVM performed qualitative and quantitative analysis using UHPLC quadrupole time-of-flight mass spectrometry. Sciensano carried out qualitative analysis using UHPLC quadrupole-Orbitrap mass spectrometry. Seventeen brands of supplements were analyzed. Many brands included more than one prohibited stimulant in the same product: 4 brands (24%, 4/17) included 2 stimulants, 2 (12%, 2/17) combined 3 stimulants, and 2 (12%, 2/17) combined 4 stimulants. The range of quantities per recommended serving size of the 9 stimulants detected were 2.7 mg to 17 mg of deterenol; 1.3 mg to 20 mg of phenpromethamine (Vonedrine); 5.7 mg to 92 mg of beta-methylphenylethylamine (BMPEA); 18 mg to 73 mg of octodrine; 18 mg to 55 mg of oxilofrine; 48 mg of higenamine; 17 mg of 1,3-dimethylamylamine (1,3-DMAA); 1.8 mg to 6.6 mg of 1,3-dimethylbutylamine (1,3-DMBA); and 5.3 mg of 1,4-dimethylamylamine (1,4-DMAA). Weight loss and sports supplements listing deterenol as an ingredient contained 9 prohibited stimulants and 8 different mixtures of stimulants, with as many as 4 experimental stimulants per product. These cocktails of stimulants have never been tested in humans and their safety is unknown.

Sections du résumé

BACKGROUND BACKGROUND
Weight loss and sports supplements containing deterenol have been associated with serious adverse events including cardiac arrest.
OBJECTIVE OBJECTIVE
To determine the presence and quantity of experimental stimulants in dietary supplements labeled as containing deterenol sold in the United States.
METHODS METHODS
Dietary supplements available for sale in the US and labeled as containing deterenol or one of its synonyms (e.g., isopropylnorsynephrine and isopropyloctopamine) were purchased online. For each brand, one container or subsample was analyzed by NSF International (Ann Arbor, MI) and one container or subsample by the Netherland's National Institute for Public Health and the Environment (RIVM, Bilthoven, The Netherlands). When differences existed between the two containers or subsamples of the same brand, both products were reanalyzed by Sciensano (Brussels, Belgium). NSF International carried out qualitative and quantitative analyses using ultra-high-performance liquid chromatography (UHPLC) quadrupole-Orbitrap mass spectrometry. RIVM performed qualitative and quantitative analysis using UHPLC quadrupole time-of-flight mass spectrometry. Sciensano carried out qualitative analysis using UHPLC quadrupole-Orbitrap mass spectrometry.
RESULTS RESULTS
Seventeen brands of supplements were analyzed. Many brands included more than one prohibited stimulant in the same product: 4 brands (24%, 4/17) included 2 stimulants, 2 (12%, 2/17) combined 3 stimulants, and 2 (12%, 2/17) combined 4 stimulants. The range of quantities per recommended serving size of the 9 stimulants detected were 2.7 mg to 17 mg of deterenol; 1.3 mg to 20 mg of phenpromethamine (Vonedrine); 5.7 mg to 92 mg of beta-methylphenylethylamine (BMPEA); 18 mg to 73 mg of octodrine; 18 mg to 55 mg of oxilofrine; 48 mg of higenamine; 17 mg of 1,3-dimethylamylamine (1,3-DMAA); 1.8 mg to 6.6 mg of 1,3-dimethylbutylamine (1,3-DMBA); and 5.3 mg of 1,4-dimethylamylamine (1,4-DMAA).
CONCLUSION CONCLUSIONS
Weight loss and sports supplements listing deterenol as an ingredient contained 9 prohibited stimulants and 8 different mixtures of stimulants, with as many as 4 experimental stimulants per product. These cocktails of stimulants have never been tested in humans and their safety is unknown.

Identifiants

pubmed: 33755516
doi: 10.1080/15563650.2021.1894333
doi:

Substances chimiques

1,3-dimethylamylamine 0
1,4-dimethylamylamine 0
2-amino-6-methylheptane 0
Adrenergic Agonists 0
Alkaloids 0
Amines 0
Amphetamines 0
Anti-Obesity Agents 0
Central Nervous System Stimulants 0
Heptanes 0
Tetrahydroisoquinolines 0
beta-methylphenyl-ethylamine 0
Octopamine 14O50WS8JD
deterenol BR971OUC9M
oxilofrine F49638UBDR
Ephedrine GN83C131XS
1,3-dimethylbutylamine KXP599H5R6
higenamine TBV5O16GAP

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

975-981

Commentaires et corrections

Type : ErratumIn

Auteurs

Pieter A Cohen (PA)

Department of Medicine, Cambridge Health Alliance, Somerville, MA, USA.
Harvard Medical School, Boston, MA, USA.

John C Travis (JC)

NSF International, Ann Arbor, MI, USA.

Céline Vanhee (C)

Department of Medicines and Health Products, Sciensano, Belgium.

Dana Ohana (D)

Health Protection Center, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.

Bastiaan J Venhuis (BJ)

Health Protection Center, National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH